1
|
Liao D, Aminilari M, Tsao M, Ahmed S, Ye XY, Metser U, Prica A, Singnurkar A, Hodgson D. Management and Outcomes of Hodgkin Lymphoma Patients Who Achieve Partial Metabolic Response on PET Scans Post-Chemotherapy. Int J Radiat Oncol Biol Phys 2023; 117:S61-S62. [PMID: 37784539 DOI: 10.1016/j.ijrobp.2023.06.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Optimal management of patients with Hodgkin Lymphoma (HL) who do not achieve PET (positron emission tomography) complete metabolic response after primary systemic therapy is unclear. Options vary significantly and include radiation therapy (RT) to localized sites of PET avid disease, salvage chemotherapy followed by autologous stem-cell transplantation (ASCT), or observation with serial imaging. This multi-center study sought to investigate the management approaches and outcomes for HL patients who achieved partial metabolic response after primary systemic therapy. MATERIALS/METHODS In this retrospective study, patients diagnosed with HL were identified from the electronic medical records database of two large academic centers between January 2009 and September 2021. PET scan results following initial chemotherapy were reviewed and responses were categorized using International Working Group (IWG) criteria, with the initial staging imaging being used as the reference against which response was evaluated. We performed descriptive analysis of demographic and clinical characteristics of the population and Kaplan-Meier estimates were used to determine progression-free survival (PFS). RESULTS The charts of 1,093 HL patients were reviewed. A total of 765 patients had a post chemotherapy PET scan with 57 of those showing partial metabolic response. Among these 57 patients, 31 (54%) were male, the median age at diagnosis was 31 (range:18-74), and the median length of follow up was 1.6 years (average 2.9 years). Five percent stage I, 32% stage II, 23% stage III, and 40% stage IV. Typical initial chemotherapy included ABVD, ABVD switched to BEACOPP due to abnormal interim PET, and AVD with Brentuximab. Among all patients with metabolic partial response to chemotherapy, the 2-year PFS was 72.8% (95% CI = 60.9-87%). Thirty-three of these patients (58%) were treated with planned radiation therapy alone, and 2-year PFS was 80.7% (95% CI = 66.6-97.9%). For those who did not receive radiation as part of their treatment, progression rate was 38% at 2 years. CONCLUSION To our knowledge, this is the largest series of HL patients with partial metabolic response following primary chemotherapy. Our preliminary analysis showed that treatment with radiation was associated with good PFS at 2 years and many of those treated with radiation alone were cured.
Collapse
Affiliation(s)
- D Liao
- University of Toronto, Toronto, ON, Canada
| | - M Aminilari
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - M Tsao
- Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| | - S Ahmed
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - X Y Ye
- Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - U Metser
- Joint Department of Medical Imaging, University Health Network, Toronto, ON, Canada
| | - A Prica
- Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - A Singnurkar
- Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - D Hodgson
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| |
Collapse
|
2
|
Pitters E, Puts M, Alqurini N, Strohschein F, Koneru R, Szumacher E, Mariano C, Monette J, Hsu T, Brennenstuhl S, McLean B, Wills A, Berger A, Amir E, Romanovsky L, Li A, Mehta R, Krzyzanowska M, Elser C, Jang R, Prica A, Wan-Chow-Wah D, Emmenegger U, Menjak I, Bergman S, Lemonde M, Krahn M, Beland F, Breunis H, Alibhai S. The impact of the COVID-19 pandemic on quality of life, health care use and mortality in older adults in the 5C study of geriatric assessment and management: secondary analysis. J Geriatr Oncol 2022. [PMCID: PMC9595410 DOI: 10.1016/s1879-4068(22)00376-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
3
|
Puts M, Alqurini N, Strohschein F, Berger A, Romanovsky L, Monette J, Mehta R, Li A, Wan-Chow-Wah D, Hsu T, Brennenstuhl S, Koneru R, Szumacher E, Mariano C, McLean B, Wills A, Amir E, Krzyzanowska M, Elser C, Jang R, Prica A, Pitters E, Emmenegger U, Menjak I, Bergman S, Lemonde M, Breunis H, Beland F, Krahn M, Alibhai S. Recommendations and adherence to recommendations made based on a comprehensive geriatric assessment for Canadian older adults with cancer: Results of the 5C trial. J Geriatr Oncol 2022. [DOI: 10.1016/s1879-4068(22)00374-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
4
|
Suleman A, Aktar S, Liu N, Chan K, Cheung M, Prica A. BENDAMUSTINE‐RITUXIMAB COMPARED TO RITUXIMAB‐CHOP/CVP FOR TREATMENT OF PATIENTS WITH INDOLENT LYMPHOMA IN ONTARIO: A POPULATION‐BASED STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.28_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Suleman
- University of Toronto, Department of Medicine Toronto Canada
| | - S. Aktar
- Institute for Clinical Evaluative Sciences, (ICES) Toronto Canada
| | - N. Liu
- Institute for Clinical Evaluative Sciences, (ICES) Toronto Canada
| | - K. Chan
- Sunnybrook Health Sciences Centre Odette Cancer Centre Toronto Canada
| | - M. Cheung
- Sunnybrook Health Sciences Centre Odette Cancer Centre Toronto Canada
| | - A. Prica
- Princess Margaret Cancer Centre Cancer Clinical Research Unit Toronto Canada
| |
Collapse
|
5
|
Manji F, Bhella S, Kridel R, Kukreti V, Kuruvilla J, Prica A, Crump M. CLINICAL UTILITY OF INTERIM CT SCANS IN PATIENTS RECEIVING CHEMOIMMUNOTHERAPY FOR FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.35_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F. Manji
- Princess Margaret Cancer Centre Department of Medical Oncology and Hematology Toronto Canada
| | - S. Bhella
- Princess Margaret Cancer Centre Department of Medical Oncology and Hematology Toronto Canada
| | - R. Kridel
- Princess Margaret Cancer Centre Department of Medical Oncology and Hematology Toronto Canada
| | - V. Kukreti
- Princess Margaret Cancer Centre Department of Medical Oncology and Hematology Toronto Canada
| | - J. Kuruvilla
- Princess Margaret Cancer Centre Department of Medical Oncology and Hematology Toronto Canada
| | - A. Prica
- Princess Margaret Cancer Centre Department of Medical Oncology and Hematology Toronto Canada
| | - M. Crump
- Princess Margaret Cancer Centre Department of Medical Oncology and Hematology Toronto Canada
| |
Collapse
|
6
|
Lebel E, Jain MD, Prica A, Kukreti V, Kridel R, Laister RC, Meng L, Delabie J, Weiss J, Panzarella T, Crump M, Kuruvilla J. PROSPECTIVE VALIDATION OF RECIL RESPONSE CRITERIA: RESULTS OF OBINUTUZUMAB‐GDP AS SALVAGE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN AGGRESSIVE B CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.97_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- E. Lebel
- Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - M. D. Jain
- Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy Tampa Florida USA
| | - A. Prica
- Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - V. Kukreti
- Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - R. Kridel
- Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - R. C. Laister
- Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - L. Meng
- Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - J. Delabie
- Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - J. Weiss
- Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - T. Panzarella
- Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - M. Crump
- Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - J. Kuruvilla
- Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| |
Collapse
|
7
|
Lang N, De la Torre A, Kridel R, Prica A, Crump M, Kukreti V, Kuruvilla J, Tsang R, Hodgson D, Rodin D, Bhella S. PRIMARY CENTRAL NERVOUS SYSTEM POST‐TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (CNS‐PTLD): A 20 YEARS RETROSPECTIVE SINGLE CENTER EXPERIENCE. Hematol Oncol 2021. [DOI: 10.1002/hon.70_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- N. Lang
- Princess Margaret Hospital Haematology Toronto Canada
| | | | - R. Kridel
- Princess Margaret Hospital Haematology Toronto Canada
| | - A. Prica
- Princess Margaret Hospital Haematology Toronto Canada
| | - M. Crump
- Princess Margaret Hospital Haematology Toronto Canada
| | - V. Kukreti
- Princess Margaret Hospital Haematology Toronto Canada
| | - J. Kuruvilla
- Princess Margaret Hospital Haematology Toronto Canada
| | - R. Tsang
- Princess Margaret Hospital Haematology Toronto Canada
| | - D. Hodgson
- Princess Margaret Hospital Haematology Toronto Canada
| | - D. Rodin
- Princess Margaret Hospital Haematology Toronto Canada
| | - S. Bhella
- Princess Margaret Hospital Haematology Toronto Canada
| |
Collapse
|
8
|
Fehr M, Lang N, Rubio L, Güsewell S, Templeton A, Aeppli S, Tsang R, Hodgson D, Moccia A, Bargetzi M, Caspar C, Brülisauer DMA, Ebnöther M, Fischer N, Prica A, Kukreti V, Ghilardi G, Krasniqi F, Mey UJ, Mingrone W, Novak U, Richter P, Kridel R, Rodin D, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Crump M, Hitz F, Kuruvilla J. PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASES. Hematol Oncol 2021. [DOI: 10.1002/hon.113_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M Fehr
- Cantonal Hospital St. Gallen, Medical Oncology and Haematology St. Gallen Switzerland
| | - N Lang
- Hôpitaux Universitaires Genève, Department of Oncology Genève Switzerland
| | - L Rubio
- Manchester Royal Infirmary, Haematology Manchester UK
| | - S Güsewell
- Cantonal Hospital St. Gallen, Clinical Trials Unit St. Gallen Switzerland
| | - A.J. Templeton
- Claraspital Basel, Oncology and Haematology Basel Switzerland
| | - S Aeppli
- Cantonal Hospital St. Gallen, Medical Oncology and Haematology St. Gallen Switzerland
| | - R Tsang
- Princess Margaret Cancer Centre, Medical Oncology and Haematology Toronto Canada
| | - D Hodgson
- Princess Margaret Cancer Centre, Medical Oncology and Haematology Toronto Canada
| | - A Moccia
- Oncology Institute of Southern Switzerland, Department of Medical Oncology Bellinzona Switzerland
| | - M Bargetzi
- Cantonal Hospital Aarau, Haematology Aarau Switzerland
| | - C Caspar
- Cantonal Hospital Baden, Oncology und Haematology Baden Switzerland
| | | | - M Ebnöther
- Claraspital Basel, Oncology and Haematology Basel Switzerland
| | - N Fischer
- Cantonal Hospital Winterthur, Medical Oncology and Haematology Winterthur Switzerland
| | - A Prica
- Princess Margaret Cancer Centre, Medical Oncology and Haematology Toronto Canada
| | - V Kukreti
- Princess Margaret Cancer Centre, Medical Oncology and Haematology Toronto Canada
| | - G Ghilardi
- Oncology Institute of Southern Switzerland, Haematology Bellinzona Switzerland
| | - F Krasniqi
- University Hospital Basel, Oncology Basel Switzerland
| | - U. J Mey
- Cantonal Hospital Grisons, Oncology and Haematology Chur Switzerland
| | - W Mingrone
- Cantonal Hospital Olten, Centre for Oncology Olten Switzerland
| | - U Novak
- University Hospital Bern, Medical Oncology Bern Switzerland
| | - P Richter
- Cantonal Hospital Grisons, Oncology and Haematology Chur Switzerland
| | - R Kridel
- Princess Margaret Cancer Centre, Medical Oncology and Haematology Toronto Canada
| | - D Rodin
- Princess Margaret Cancer Centre, Radiation Oncology Toronto Switzerland
| | - M Rütti
- Hospital Wil, Medicine Wil Switzerland
| | - A Schmidt
- Stadtspital Triemli, Medical Oncology und Haematology Zürich Switzerland
| | | | - M Voegeli
- Cantonal Hospital Baselland, Oncology and Haematology Liestal Switzerland
| | - T Zander
- Cantonal Hospital Luzern, Medical Oncology Luzern Switzerland
| | - M Crump
- Princess Margaret Cancer Centre, Medical Oncology and Haematology Toronto Canada
| | - F Hitz
- Cantonal Hospital St. Gallen, Medical Oncology and Haematology St. Gallen Switzerland
| | - J Kuruvilla
- Princess Margaret Cancer Centre, Medical Oncology and Haematology Toronto Canada
| |
Collapse
|
9
|
Puts M, Strohschein F, Mclean B, Alqurini N, Syed A, Amir E, Béland F, Berger A, Bergman S, Vanderbyl B, Breunis H, Elser C, Emmenegger U, Fung S, Hsu T, Jang R, Krahn M, Koneru R, Kozlowski N, Krzyzanowska M, Lemonde M, Li A, Mariano C, Mehta R, Monette J, Papadakos J, Pitters E, Prica A, Ray J, Romanofsky L, Szumacher E, Wan-Chow-Wah D, Langleben A, Alibhai S. CLINICAL AND COST-EFFECTIVENESS OF COMPREHENSIVE GERIATRIC ASSESSMENT AND MANAGEMENT FOR CANADIAN ELDERS WITH CANCER: THE 5C STUDY – INITIAL RECRUITMENT AND IMPLEMENTATION RESULTS. J Geriatr Oncol 2019. [DOI: 10.1016/s1879-4068(19)31271-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Skrabek P, Assouline S, Christofides A, MacDonald D, Prica A, Sangha R, Matthews BA, Sehn LH. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Curr Oncol 2019; 26:253-265. [PMID: 31548805 PMCID: PMC6726277 DOI: 10.3747/co.26.5421] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Diffuse large B cell lymphoma (dlbcl) is an aggressive non-Hodgkin lymphoma, accounting for approximately 30% of lymphoma cases in Canada. Although most patients will achieve a cure, up to 40% will experience refractory disease after initial treatment, or relapse after a period of remission. In eligible patients, salvage therapy followed by high-dose therapy and autologous stem-cell transplantation (asct) is the standard of care. However, many patients are transplant-ineligible, and more than half of those undergoing asct will subsequently relapse. For those patients, outcomes are dismal, and novel treatment approaches are a critical unmet need. In this paper, we present available data about emerging treatment approaches in the latter setting and provide a perspective about the potential use of those approaches in Canada.
Collapse
Affiliation(s)
- P Skrabek
- Department of Hematology and Medical Oncology, University of Manitoba, and CancerCare Manitoba, Winnipeg, MB
| | - S Assouline
- Department of Medicine, Division of Hematology, Sir Mortimer B. Davis Jewish General Hospital and McGill University, Montreal, QC
| | | | | | - A Prica
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, and University of Toronto, Toronto, ON
| | - R Sangha
- University of Alberta and Cross Cancer Institute, Edmonton, AB
| | | | - L H Sehn
- Division of Medical Oncology, University of British Columbia, and BC Cancer, Vancouver, BC
| |
Collapse
|
11
|
Samaniego F, Hollebecque A, Foss F, Lister J, Mita M, Wagner-Johnston N, Dyer M, You B, Prica A, Hernandez-Llizaliturri F, Ferraldeschi R, Chan D, Zhang J, Mehta A. PRELIMINARY RESULTS OF ASTX660, A NOVEL NON-PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.211_2631] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- F. Samaniego
- Lymphoma & Myeloma; UT MD Anderson Cancer Center; Houston United States
| | - A. Hollebecque
- Early Drug Development (DITEP) Gastro-Intestinal Oncology; Institute Gustave Roussy; Villejuif France
| | - F. Foss
- Internal Medicine; Hematology, Yale Cancer Center; New Haven United States
| | - J. Lister
- Division of Hematology and Cellular Therapy; Allegheny Health Network Cancer Institute; Pittsburgh United States
| | - M. Mita
- Experimental Therapeutics; Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center; Los Angeles United States
| | | | - M. Dyer
- Ernest and Helen Scott Haematological Research Institute; University of Leicester; Leicester United Kingdom
| | - B. You
- Medical Oncology; Centre Hospitalier Lyon Sud; Pierre Benite France
| | - A. Prica
- Hematology; Princess Margaret Cancer Centre Mount Sinai Hospital; Toronto Ontario Canada
| | | | - R. Ferraldeschi
- Clinical Development; Astex Pharmaceuticals, Inc.; Pleasanton United States
| | - D. Chan
- Clinical Development; Astex Pharmaceuticals, Inc.; Pleasanton United States
| | - J. Zhang
- Clinical Development; Astex Pharmaceuticals, Inc.; Pleasanton United States
| | - A. Mehta
- Hematology and Oncology; University of Alabama at Birmingham; Birmingham United States
| |
Collapse
|
12
|
Prica A, Vijenthira A, Chan K, Cheung M. COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF MULTIPLE TREATMENT STRATEGIES USING ABVD AND/OR BEACOPP IN THE TREATMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.106_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Prica
- Department of Hematology/Medical Oncology; Princess Margaret Cancer Centre; Toronto Canada
| | - A. Vijenthira
- Postgraduate Medicine; University of Toronto; Toronto Canada
| | - K. Chan
- Department of Hematology/Medical Oncology; Sunnybrook Health Sciences Centre; Toronto Canada
| | - M. Cheung
- Department of Hematology/Medical Oncology; Sunnybrook Health Sciences Centre; Toronto Canada
| |
Collapse
|
13
|
Liu J, Biccler J, Stewart D, Fontaine A, Peters A, Fleury I, Mollica L, Prica A, Buckstein R, Kuruvilla J, Villa D. CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA FOLLOWING RETREATMENT WITH SECOND-LINE RITUXIMAB-CONTAINING CHEMOTHERAPY. Hematol Oncol 2019. [DOI: 10.1002/hon.67_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J. Liu
- Division of Adult and Pediatric Hematology; University of Toronto; Toronto Canada
| | - J.L. Biccler
- Department of Clinical Medicine; Aarlborg University; Aarlborg Denmark
| | - D. Stewart
- Tom Baker Cancer Centre; University of Calgary; Calgary Canada
| | - A. Fontaine
- Cross Cancer Institute; University of Alberta; Edmonton AB Canada
| | - A. Peters
- Cross Cancer Institute; University of Alberta; Edmonton AB Canada
| | - I. Fleury
- Universite de Montreal; Hôpital Maisonneuve-Rosemont; Montreal QC Canada
| | - L. Mollica
- Universite de Montreal; Hôpital Maisonneuve-Rosemont; Montreal QC Canada
| | - A. Prica
- University of Toronto; Princess Margaret Cancer Centre; Toronto ON Canada
| | - R. Buckstein
- University of Toronto; Odette Cancer Centre - Sunnybrook Health Sciences Centre; Toronto ON Canada
| | - J. Kuruvilla
- University of Toronto; Princess Margaret Cancer Centre; Toronto ON Canada
| | - D. Villa
- University of British Columbia; BC Cancer Centre for Lymphoid Cancer; Vancouver BC Canada
| |
Collapse
|
14
|
Prica A, Dhir V, Maganti M, Kukreti V, Kuruvilla J, Crump M. FUNCTIONAL PREDICTORS OF CHEMOTHERAPY TOXICITY IN ELDERLY LYMPHOMA PATIENTS - A PROSPECTIVE PILOT STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.228_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Prica
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - V. Dhir
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - M. Maganti
- Biostatistics; Princess Margaret Cancer Centre; Toronto Canada
| | - V. Kukreti
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - J. Kuruvilla
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - M. Crump
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| |
Collapse
|
15
|
Tang C, Espin-Garcia O, Prica A, Kukreti V, Kridel R, Keating A, Kuruvilla J, Crump M. EFFICIENCY AND SAFETY OF STEM CELL MOBILIZATION FOLLOWING GDP SALVAGE IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.112_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C. Tang
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - O. Espin-Garcia
- Biostatistics; Princess Margaret Cancer Centre; Toronto Canada
| | - A. Prica
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - V. Kukreti
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - R. Kridel
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - A. Keating
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - J. Kuruvilla
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - M. Crump
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| |
Collapse
|
16
|
Prica A, Dhir V, Zibdawi L, Espin-Garcia O. QUALITY OF LIFE AND CAREGIVER BURDEN IN MULTIPLE MYELOMA AND LYMPHOMA PATIENTS UNDERGOING OUTPATIENT AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS INPATIENT TRANSPLANTATION. Hematol Oncol 2019. [DOI: 10.1002/hon.232_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Prica
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - V. Dhir
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - L. Zibdawi
- Medical Oncology and Hematology; Princess Margaret Cancer Centre; Toronto Canada
| | - O. Espin-Garcia
- Department of Biostatistics; Princess Margaret Cancer Centre; Toronto Canada
| |
Collapse
|
17
|
Kuruvilla J, Crump M, Villa D, Aslam M, Prica A, Scott D, Abdel-Samad N, Couban S, Doucet S, Dudebout J, Fleury I, Fraser G, Larouche J, Shafey M, Skrabek P, Skamene T, Winch C, Shepherd L, Chen B, Hay A. CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR-DLBCL) - OUTCOME OF IBRUTINIB + R-GDP. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_76] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J. Kuruvilla
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - M. Crump
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - D. Villa
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - M. Aslam
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - A. Prica
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - D.W. Scott
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | | | - S. Couban
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - S. Doucet
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - J. Dudebout
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - I. Fleury
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - G. Fraser
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - J. Larouche
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - M. Shafey
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - P. Skrabek
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - T. Skamene
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - C. Winch
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - L. Shepherd
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - B.E. Chen
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| | - A.E. Hay
- Canadian Cancer Trials Group; CCTG; Kingston Canada
| |
Collapse
|
18
|
MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH. Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. ACTA ACUST UNITED AC 2016; 23:407-417. [PMID: 28050137 DOI: 10.3747/co.23.3405] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
With no treatment standard having been established for relapsed and refractory follicular lymphoma, a number of therapeutic approaches are used in Canada. In patients who relapse early or who eventually become resistant to subsequent treatment, prognosis is poor, and new approaches are needed. A number of novel therapies are being examined in this setting, including monoclonal antibodies, immunoconjugates, immunomodulatory agents, and signal transduction inhibitors. With the body of evidence for those emerging therapies accumulating and the standard upfront treatment changing from rituximab and chop (cyclophosphamide-doxorubicin-vincristine-prednisone) or rituximab and cvp (cyclophosphamide-vincristine-prednisone) to bendamustine and rituximab, treatment decisions in the relapsed and refractory setting have become more complex. The choice of subsequent treatment must consider type of upfront treatment; duration of remission; and patient-related factors such as age, comorbidities, and treatment preferences. This paper summarizes the evidence for novel therapies and proposes recommendations for subsequent treatment options by remission duration after induction and maintenance.
Collapse
Affiliation(s)
- D MacDonald
- Division of Hematology, Dalhousie University, and QEII Health Sciences Centre, Halifax, NS
| | - A Prica
- Department of Medical Oncology, University of Toronto, and Princess Margaret Hospital, Toronto, ON
| | - S Assouline
- Department of Oncology, McGill University, and Jewish General Hospital, Montreal, QC
| | | | | | - L H Sehn
- Division of Medical Oncology, University of British Columbia, and BC Cancer Agency, Vancouver, BC
| |
Collapse
|
19
|
Prica A, Baldassarre F, Hicks LK, Imrie K, Kouroukis T, Cheung M. Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline. Clin Oncol (R Coll Radiol) 2016; 29:e13-e28. [PMID: 27746042 DOI: 10.1016/j.clon.2016.09.004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Revised: 06/20/2016] [Accepted: 07/05/2016] [Indexed: 11/25/2022]
Abstract
Rituximab is the first monoclonal antibody to be approved for use by the US Food and Drug Administration in cancer. Its role in the treatment of non-Hodgkin lymphoma, including chronic lymphocytic leukaemia (CLL), has evolved significantly. We aimed to systematically review and update the literature on rituximab in lymphoma and CLL, and provide evidence-based consensus guidelines for its rational use. Validated methodology from the Cancer Care Ontario Program in Evidence-based Care was used. A comprehensive literature search was completed by a methodologist from the Hematology Disease Site Group of Cancer Care Ontario. Data were extracted from randomised controlled trials of rituximab-containing chemotherapy regimens for patients with lymphoma or CLL. Fifty-six primary randomised controlled trials were retrievable and met all inclusion criteria. Clinically important benefits in progression-free survival or overall survival were seen in the following settings: (i) addition of rituximab to combination chemotherapy for initial treatment of aggressive B-cell lymphomas, including diffuse large B-cell lymphoma, Burkitt lymphoma and HIV-related lymphoma with CD4 count ≥50/mm3; (ii) addition of rituximab to combination chemotherapy for initial and subsequent treatment of follicular lymphoma and other indolent B-cell lymphomas; (iii) use of rituximab maintenance in patients with indolent B-cell lymphomas who have responded to chemoimmunotherapy; (iv) addition of rituximab to fludarabine-based chemotherapy or chlorambucil for initial treatment of CLL. The consensus opinion of the Hematology Disease Site Group is that rituximab is recommended for these indications.
Collapse
Affiliation(s)
- A Prica
- Princess Margaret Hospital, Toronto, Ontario, Canada
| | - F Baldassarre
- Program in Evidence-based Care, Cancer Care Ontario, McMaster University, Hamilton, Ontario, Canada.
| | - L K Hicks
- St. Michael Hospital, Toronto, Ontario, Canada
| | - K Imrie
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - T Kouroukis
- Juravinski Cancer Centre, Hamilton, Ontario, Canada
| | - M Cheung
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | | |
Collapse
|
20
|
Cheung MC, Prica A, Graczyk J, Buckstein R, Chan KKW. Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis. Leuk Lymphoma 2016; 57:1865-75. [PMID: 26758765 DOI: 10.3109/10428194.2015.1117609] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Granulocyte colony-stimulating factor (G-CSF) is commonly administered to patients with Hodgkin lymphoma (HL) with neutropenia. We constructed a decision-analytic model to compare the cost-effectiveness of secondary prophylaxis with G-CSF to a strategy of 'no G-CSF' in response to severe neutropenia for adults with advanced-stage HL treated with ABVD. A Canadian public health payer's perspective was considered and costs were presented in 2013 Canadian dollars. The quality-adjusted life years (QALYs) attained with the G-CSF and 'no G-CSF' strategies were 1.403 and 1.416, respectively. Costs for the strategies with and without G-CSF were $38,971 and $33,982, respectively. In the base case analysis, the 'no G-CSF' strategy was associated with cost savings and improved QALYs; therefore, 'no G-CSF' was the dominant approach. For patients with severe neutropenia during ABVD chemotherapy for advanced-stage HL, a strategy without G-CSF support is associated with improved quality-adjusted outcomes, cost savings, and is the preferred approach.
Collapse
Affiliation(s)
- M C Cheung
- a Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto , Toronto , Canada
| | - A Prica
- b Princess Margaret Hospital and Mt. Sinai Hospital, University of Toronto , Toronto , Canada
| | - J Graczyk
- c Grand River Regional Cancer Centre , Kitchener , Canada
| | - R Buckstein
- a Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto , Toronto , Canada
| | - K K W Chan
- a Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto , Toronto , Canada ;,d Division of Biostatistics , Dalla Lana School of Public Health, University of Toronto , Toronto , Canada
| |
Collapse
|
21
|
Tseng E, Prica A, Zhang L, Mittmann N, Seung SJ, Callum J, Kim T, Wells RA, Buckstein R. Monthly blood transfusions decrease after four months of azacitidine. Vox Sang 2015; 109:163-7. [PMID: 25899763 DOI: 10.1111/vox.12266] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Revised: 02/01/2015] [Accepted: 02/05/2015] [Indexed: 01/13/2023]
Abstract
BACKGROUND AND OBJECTIVES Azacitidine (AZA) improves overall survival and transfusion independence in patients with myelodysplastic syndrome (MDS). We aimed to quantify the reduction in red blood cell (RBC) transfusions and to determine when this reduction occurs, in MDS patients treated with AZA. MATERIALS AND METHODS We performed a retrospective audit of changes in RBC transfusion burden in 51 patients with predominantly higher risk MDS (26.5% high risk, 51.0% intermediate-2) who received AZA. Transfusion requirements were audited 6 months prior to and up to 18 months after therapy initiation, and data were analysed using a generalized linear mixed model. RESULTS At baseline, 30 patients (58.8%) were transfusion dependent (TD). Seventeen patients (56.7%) achieved transfusion independence (TI) by 18 months, and 8 of these patients (47.1%) achieved this response by 4 months on therapy. Achievement of TI was not consistently durable in these 17 patients, as 11 patients reverted to TD while on therapy. Meanwhile, 6 of 21 patients who were TI at baseline became TD on therapy. The monthly average of RBC units transfused decreased significantly beginning at 4 months, with a reduction from 2.50 units per month at baseline to 1.00 units per month at month 4. This 60% reduction was significant (P = 0.002) and sustained beyond 12 months. CONCLUSION These results bolster the notion that AZA significantly reduces transfusion burden and resource utilization and illustrate the limitations of the current WHO erythroid response criteria which do not account for differing durability and fluctuations of response.
Collapse
Affiliation(s)
- E Tseng
- Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - A Prica
- Princess Margaret Hospital, Toronto, ON, Canada
| | - L Zhang
- Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - N Mittmann
- Health Outcomes and PharmacoEconomic (HOPE) Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.,Department of Pharmacology, University of Toronto, Toronto, ON, Canada.,International Centre for Health Innovation, Richard Ivey School of Business, Western University, London, ON, Canada
| | - S J Seung
- Health Outcomes and PharmacoEconomic (HOPE) Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - J Callum
- Department of Clinical Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - T Kim
- Celgene Incorporated, Mississauga, ON, Canada
| | - R A Wells
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - R Buckstein
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| |
Collapse
|
22
|
Prica A, Chan K, Cheung M. Combined modality therapy versus chemotherapy alone as an induction regimen for primary central nervous system lymphoma: a cost-effectiveness analysis. Neuro Oncol 2014; 16:1384-91. [PMID: 24799455 DOI: 10.1093/neuonc/nou057] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND In immunocompetent patients with primary central nervous system lymphoma (PCNSL), combined modality therapy (CMT) using high-dose methotrexate and radiotherapy (WBRT) has improved response rates compared with chemotherapy alone. The trade-off is delayed and potentially devastating treatment-related neurotoxicity (NT). METHODS A cost-effectiveness analysis using a Markov model compared CMT with chemotherapy alone in age-stratified patients with PCNSL. Baseline probabilities were derived from a systematic literature review. Direct and lost productivity costs were collected from a Canadian perspective and presented in Can$ in 2011. Outcomes were life expectancy, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio. RESULTS The quality-adjusted life expectancy was 1.55 QALYs for CMT and 1.53 QALYs for chemotherapy alone. In younger patients (aged <60 years), CMT yielded 2.44 QALYs, compared with 1.89 QALYs for chemotherapy alone, yielding an expected benefit with CMT of 0.55 QALYs or 6.6 quality-adjusted months. The CMT strategy dominated in younger patients, as it was Can$11 951 less expensive than chemotherapy alone. The chemotherapy-alone strategy dominated in older patients, as it was Can$11 244 less expensive than CMT, and there was no difference in QALYs between the strategies. The model was robust in sensitivity analyses of key variables tested through the plausible ranges obtained from costing sources and published literature. CONCLUSION The preferred induction strategy for younger patients with PCNSL appears to be CMT, which minimized cost while maximizing life expectancy and QALYs. This analysis confirms that the preferred strategy for older patients is chemotherapy alone.
Collapse
Affiliation(s)
- A Prica
- Division of Hematology, Department of Medicine, Sunnybrook Health Science Centre, University of Toronto, Toronto, Canada (A.P., M.C.); Division of Medical Oncology, Department of Medicine, Sunnybrook Health Science Centre and Princess Margaret Hospital, University of Toronto, Toronto, Canada (K.C.)
| | - K Chan
- Division of Hematology, Department of Medicine, Sunnybrook Health Science Centre, University of Toronto, Toronto, Canada (A.P., M.C.); Division of Medical Oncology, Department of Medicine, Sunnybrook Health Science Centre and Princess Margaret Hospital, University of Toronto, Toronto, Canada (K.C.)
| | - M Cheung
- Division of Hematology, Department of Medicine, Sunnybrook Health Science Centre, University of Toronto, Toronto, Canada (A.P., M.C.); Division of Medical Oncology, Department of Medicine, Sunnybrook Health Science Centre and Princess Margaret Hospital, University of Toronto, Toronto, Canada (K.C.)
| |
Collapse
|
23
|
Prica A, Wells R, Buckstein R, Chodirker L. P-317 Immunosuppressive therapy for patients with myelodysplastic syndrome: A single centre experience. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70364-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Prica A, Tseng E, Wells R, Mamedov A, Zhang L, Lenis M, Buckstein R. P-127 Predictors of azacitidine response: A prospective longitudinal assessment. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70175-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Prica A, Tseng E, Wells R, Alibhai S, Lam A, Mamedov A, Chodirker L, Zhang L, Khalaf D, Lenis M, Buckstein R. P-257 The effects of azacitidine on quality of life: A prospective longitudinal assessment. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70304-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
26
|
Abstract
Dentin bonding agents became unavoidable in today's aesthetic restorative dentistry. Nevertheless, more and more evidences on their possible cytotoxicity and/or genotoxicity emerge. Still, only limited number of studies has been published on that issue. In our work we evaluated possible genotoxicity of five different adhesives: Adper Single Bond, Adper Single Bond 2 with nanofiller, Excite, OptiBond Solo Plus and Prompt L-pop. Genotoxicity assessment was carried out on human lymphocytes in vitro, using chromosomal aberration analysis. Polymerized adhesives were tested at three different dilutions of the 0.5 g mL(-1) eluate stock (2.5 x 1:10(6), 1:10(6) and 1:10(5)) after 1 h, 24 h and 5 days of elution. Slight but significant increase in the number of chromatid breaks was observed after 24-h elution period, for adhesives Adper Single Bond 2, Excite, and OptiBond Solo Plus at dilutions of 1:10(6) and 1:10(5), and for other two only at dilution of 1:10(5). First three adhesives also appeared to be slightly genotoxic after 1 h of elution but only at 1:10(5). As a bonding agent remains in close contact with living dental tissue over a long period of time, information on their possible genotoxicity and carcinogenicity should be more clearly clarified in the near future.
Collapse
Affiliation(s)
- D Prica
- School of Dentistry, University of Zagreb, Zagreb, Croatia
| | | | | | | |
Collapse
|
27
|
Schlaeppi M, Prica A, de Torrenté A. [Cerebral hemorrhage and "ecstasy"]. Praxis (Bern 1994) 1999; 88:568-572. [PMID: 10235031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
We report the case of an acute cerebral hemorrhage after one "ecstasy" tablet in a 21 year old woman without any relevant medical or surgical history. The status showed a right sensorimotor syndrome. The CT-scan and the MRI revealed a left cerebral hemorrhage. The patient only partially recovered her neurological functions after one year. The discussion deals with the effects and dangers of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) which is systematically used in night parties or "raves".
Collapse
Affiliation(s)
- M Schlaeppi
- Département de Médecine Interne, Hôpital Communal, La Chaux-de-Fonds
| | | | | |
Collapse
|
28
|
Prica A. [General considerations on the somatic equivalents in depressive states]. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir 1988; 33:241-8. [PMID: 3076259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
29
|
Prica A. [Clinico-catamnestic aspects of affective psychoses of the pre-senescent period]. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir 1980; 24:49-59. [PMID: 6446130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
30
|
Predescu V, Prica A, Meiu G, Popovici E, Dumitrescu V, Mihu S, Nica S, Roman I, Aloman A. [Aspects of mental disease in the personnel of an industrial unit in Bucharest and analysis of the high risk factors for neuroses]. Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir 1979; 24:117-26. [PMID: 504845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
31
|
Predescu V, Nica ST, Meiu G, Prica A, Cucu I, Damian N, Popovici I, Roman I, Grigoroiu M, Curelaru S. Observations on neurasthenia and neurasthenia-like syndromes in a group of women working in textile industry. Neurol Psychiatr (Bucur) 1976; 14:245-52. [PMID: 1024262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
32
|
Abstract
The averaged photic-evoked responses (APER) and their dispersion pattern (DP) were investigated in tired subjects, neurotics and patients with neurotic syndromes. The appearance of an ample late negative deflection (N3) followed by a deep positive one (P3) of APER and of an atypical DP in tired subjects, neurotics and in patients with neurotic syndromes, may be considered signs of tiredness and of attention lability. A lengthening of the latencies and decrease in amplitude of different APER components, found in neurotics and in patients with neurotic syndromes only, indicated abnormalities in the function of neuronal structures involved in the organizations of responses to peripheral stimuli.
Collapse
|